PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

This study (called PRIMA) is testing a combination of three treatments — a PARP inhibitor (a targeted drug that attacks cancer DNA repair), stereotactic body radiation therapy (precise, high-dose radiation), and immunotherapy — for people with advanced or metastatic high-grade sarcoma, a rare type of cancer affecting bones or soft tissues. **You may be eligible if...** - You have been diagnosed with high-grade sarcoma of the bone or soft tissue - Your cancer has spread to distant sites (metastatic) or is locally advanced and cannot be fully removed by surgery - You are able to give written informed consent - You meet other medical criteria confirmed by the study team **You may NOT be eligible if...** - Your sarcoma is low-grade - You have not been histologically confirmed (diagnosed through tissue biopsy) - You are unable to participate due to other medical conditions Talk to your doctor to see if this trial is right for you.